Physician

Sreenivas Chintalapani, M.D.

According to 2025 Medicare claims, Sreenivas Chintalapani, M.D. (NPI: 1255320511) practices gastroenterology in the Davenport-Moline-Rock Island, IA-IL market, with the plurality of this provider's patient population coming from Rock Island, IL. This provider's primary affiliated billing organization is GASTROINTESTINAL CLINIC OF QUAD CITIES, P.C. (NPI: 1942380605; TIN: 421168366) and primary practice location at 61265-6867. Chintalapani is affiliated with the Genesis Accountable Care Organization, LLC. (ACO ID: A4799) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Chintalapani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 504 traditional Medicare patients, billed 3,182 HCPCS/CPT codes, and received $155,926 in Medicare payments. The top billing code was 45385 (Removal of polyps or growths of large bowel using an endoscope with mechanical snare). Part D data shows 1,135 prescription claims across 439 beneficiaries totaling $397,773 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 7 records totaling $140. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $314,099 to $155,926. Similarly, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $609,185 to $397,773. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,724	4,902	$314,099
2016	1,548	4,215	$270,737
2017	1,400	4,777	$278,427
2018	1,353	4,349	$223,179
2019	799	1,953	$158,898
2020	655	1,353	$137,872
2021	677	1,317	$143,581
2022	590	1,735	$131,471
2023	585	3,429	$164,853
2024	504	3,182	$155,926

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	469	1,736	$609,185
2016	606	1,763	$828,461
2017	484	1,471	$589,776
2018	355	1,083	$302,674
2019	333	847	$557,667
2020	375	1,063	$284,206
2021	455	1,257	$292,495
2022	494	1,182	$321,599
2023	470	1,131	$298,815
2024	439	1,135	$397,773

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
45385	Removal of polyps or growths of large bowel using an endoscope with mechanical snare	203	204	$194
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	101	101	$114
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	149	177	$89
43239	Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	119	126	$66
88305	Pathology examination of tissue using a microscope, intermediate complexity	287	932	$25

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	24	672	$209,171
Linzess	Linaclotide	48	1,860	$32,157
Creon	Lipase/Protease/Amylase	29	822	$31,487
Mesalamine	Mesalamine	28	1,990	$13,881
Omeprazole	Omeprazole	330	19,172	$3,994

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$140	Mauna Kea Technologies, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sreenivas Chintalapani, M.D.?

Tedicare shows public-source Medicare data for Sreenivas Chintalapani, M.D. (NPI 1255320511), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sreenivas Chintalapani, M.D. have ACO affiliation data?

Sreenivas Chintalapani, M.D. is shown with ACO affiliation data for Genesis Accountable Care Organization, LLC. (MSSP, ACO ID A4799) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Sreenivas Chintalapani, M.D.?

Sreenivas Chintalapani, M.D. is linked to GASTROINTESTINAL CLINIC OF QUAD CITIES, P.C. (billing NPI 1942380605) in the available physician profile data.

Does Sreenivas Chintalapani, M.D. have Open Payments data?

Sreenivas Chintalapani, M.D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.